Latest News about DSNKY
Recent news which mentions DSNKY
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
September 23, 2024
From Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
From Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
From Benzinga
Tickers
DSNKY
From InvestorPlace
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
From Benzinga
Tickers
DSNKY
From InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
April 29, 2024
From Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
From Benzinga
What's Going On With Pfizer Stock Today?
January 25, 2024
From Benzinga
From Benzinga
From Benzinga
From Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
From Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
From Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
From Benzinga
From Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
From Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
June 27, 2023
Tickers
DSNKY
From Benzinga
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
From Benzinga
First Republic Bank sinks on possible sale reports, and Credit Suisse’s stock boosted by central bank borrowing
March 16, 2023
From MarketWatch
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
From Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
From Motley Fool
From Benzinga
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|